Eli Lilly names new business leaders

Eli Lilly, in conjunction with announcing a new operating model aimed at savings of around $1 billion in the next two years (see separate story) has named the leaders of its Development Center of Excellence and its five business units: oncology, diabetes, established markets, emerging markets, and Elanco animal health.

The new leaders are:

Tim Garnett and Tom Verhoeven, who will lead the Development Center of Excellence within Lilly Research Laboratories. Dr Garnett will have responsibility for medical, regulatory, global product safety, translational medicine and global health outcomes. Dr Verhoeven will have responsibility for the clinical development organization, product R&D, toxicology/ADME and project management.

John Johnson will lead the oncology business unit. He currently serves as chief executive of ImClone Systems, a wholly-owned subsidiary of Lilly.

Enrique Conterno will lead the diabetes business unit. He is now president of Lilly USA, the company's US business operations.

Bryce Carmine will lead the established markets business unit. He currently serves as Lilly's executive vice president of global marketing and sales.

Jacques Tapiero will lead the emerging markets business unit. At present, he is Lilly's president of the intercontinental region.

Jeffrey Simmons will lead Elanco, the animal health business unit, where he currently serves as president.

Appointments for each of the four pharmaceutical business unit leaders and the two leaders of the Development Center of Excellence will become effective on November 1, 2009.